InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,105.20
(
1.45%
)
Dow Jones
38,225.66
(
0.85%
)
Brent Oil
83.56
(
0.02%
)
Bitcoin
59,317.35
(
1.85%
)
Post# of 251689
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119553
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech jim post# 177144

Wednesday, 07/23/2014 7:17:25 PM

Wednesday, July 23, 2014 7:17:25 PM

Post# of 251689
GILD posts $3.48B in 2Q14 Sovaldi sales (+53% vs 1Q14):

http://finance.yahoo.com/news/gilead-sciences-announces-second-quarter-200500437.html

Of the $3.48B total, $3.0B was from the US, $400M was from France and Germany (the two large EU countries that have negotiated reimbursement rates), and about $80M was from the rest of the world.

In the US market, 60% of Sovaldi prescriptions were for GT1 patients (down from 70% in 1Q14), 25% for GT2, 10% for GT3, and 5% for GT4,5,6.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up